Elevated cerebrospinal fluid sphingomyelin levels in prodromal Alzheimer's disease

Neuroscience Letters

Volumn 516, Issue 2, 2012, Pages 302-305

  Kosicek, M ^a   Zetterberg, H ^b   Andreasen, N ^c   Peter Katalinic, J ^d,e   Hecimovic, S ^a  

^a RUDER BO KOVI INSTITUTE   (Croatia)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d UNIVERSITY OF MÜNSTER   (Germany)

^e University of Rijeka   (Croatia)

Author keywords

Alzheimer's disease; Cerebrospinal fluid; Mass spectrometry; Sphingomyelin

Indexed keywords

SPHINGOMYELIN;

AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MASS SPECTROMETRY; PRIORITY JOURNAL;

AGED; ALZHEIMER DISEASE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; EARLY DIAGNOSIS; FEMALE; HUMANS; MALE; PILOT PROJECTS; SPHINGOMYELINS;

EID: 84860488306     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2012.04.019     Document Type: Article

References (20)

1. Bandaru V.V., Troncoso J., Wheeler D., Pletnikova O., Wang J., Conant K., Haughey N.J. ApoE4 disrupts sterol and sphingolipid metabolism in Alzheimer's but not normal brain. Neurobiology of Aging 2009, 30:591-599.
2. Blennow K., Hampel H., Weiner M., Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nature Reviews Neurology 2010, 6:131-144.
3. Cutler R.G., Kelly J., Storie K., Pedersen W.A., Tammara A., Hatanpaa K., Troncoso J.C., Mattson M.P. Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America 2004, 101:2070-2075.
4. Dubois B., Feldman H.H., Jacova C., Dekosky S.T., Barberger-Gateau P., Cummings J., Delacourte A., Galasko D., Gauthier S., Jicha G., Meguro K., O'brien J., Pasquier F., Robert P., Rossor M., Salloway S., Stern Y., Visser P.J., Scheltens P. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurology 2007, 6:734-746.
5. Fagan A.M., Head D., Shah A.R., Marcus D., Mintun M., Morris J.C., Holtzman D.M. Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly. Annals of Neurology 2009, 65:176-183.
6. Folstein M.F., Folstein S.E., McHugh P.R. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research 1975, 12:189-198.
7. Haimi P., Uphoff A., Hermansson M., Somerharju P. Software tools for analysis of mass spectrometric lipidome data. Analytical Chemistry 2006, 78:8324-8331.
8. Han X., Fagan A.M., Cheng H., Morris J.C., Xiong C., Holtzman D.M. Cerebrospinal fluid sulfatide is decreased in subjects with incipient dementia. Annals of Neurology 2003, 54:115-119.
9. Han X., Holtzman M., McKeel D.W., Kelley J., Morris J.C. Substantial sulfatide deficiency and ceramide elevation in very early Alzheimer's disease: potential role in disease pathogenesis. Journal of Neurochemistry 2002, 82:809-818.
10. Hartmann T., Kuchenbecker J., Grimm M.O. Alzheimer's disease: the lipid connection. Journal of Neurochemistry 2007, 103(Suppl. 1):159-170.
11. He X., Huang Y., Li B., Gong C.X., Schuchman E.H. Deregulation of sphingolipid metabolism in Alzheimer's disease. Neurobiology of Aging 2010, 31:398-408.
12. Katsel P., Li C., Haroutunian V. Gene expression alterations in the sphingolipid metabolism pathways during progression of dementia and Alzheimer's disease: a shift toward ceramide accumulation at the earliest recognizable stages of Alzheimer's disease?. Neurochemical Research 2007, 32:845-856.
13. Kosicek M., Kirsch S., Bene R., Trkanjec Z., Titlic M., Bindila L., Peter-Katalinic J., Hecimovic S. Nano-HPLC-MS analysis of phospholipids in cerebrospinal fluid of Alzheimer's disease patients - a pilot study. Analytical and Bioanalytical Chemistry 2010, 398:2929-2937.
14. G.McKhann, Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984, 34:939-944.
15. Mielke M.M., Lyketsos C.G. Alterations of the sphingolipid pathway in Alzheimer's disease: new biomarkers and treatment targets?. Neuromolecular Medicine 2010, 12:331-340.
16. Mulder C., Wahlund L.O., Teerlink T., Blomberg M., Veerhuis R., van Kamp G.J., Scheltens P., Scheffer P.G. Decreased lysophosphatidylcholine/phosphatidylcholine ratio in cerebrospinal fluid in Alzheimer's disease. Journal of Neural Transmission 2003, 110:949-955.
17. Mungas D. In-office mental status testing: a practical guide. Geriatrics 1991, 46. 54-58, 63, 66.
18. Pettegrew J.W., Panchalingam K., Hamilton R.L., McClure R.J. Brain membrane phospholipid alterations in Alzheimer's disease. Neurochemical Research 2001, 26:771-782.
19. Satoi H., Tomimoto H., Ohtani R., Kitano T., Kondo T., Watanabe M., Oka N., Akiguchi I., Furuya S., Hirabayashi Y., Okazaki T. Astroglial expression of ceramide in Alzheimer's disease brains: a role during neuronal apoptosis. Neuroscience 2005, 130:657-666.
20. Walter A., Korth U., Hilgert M., Hartmann J., Weichel O., Hilgert M., Fassbender K., Schmitt A., Klein J. Glycerophosphocholine is elevated in cerebrospinal fluid of Alzheimer patients. Neurobiology of Aging 2004, 25:1299-1303.